INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 2.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $2,123,000 | -10.0% | 106,323 | +4.1% | 0.00% | -33.3% |
| Q1 2021 | $2,358,000 | -20.2% | 102,176 | -14.6% | 0.00% | -25.0% |
| Q4 2020 | $2,956,000 | -42.2% | 119,676 | -2.9% | 0.00% | -50.0% |
| Q3 2020 | $5,111,000 | +6.9% | 123,276 | +23.5% | 0.01% | 0.0% |
| Q2 2020 | $4,782,000 | -24.6% | 99,817 | -0.8% | 0.01% | -42.9% |
| Q1 2020 | $6,338,000 | -40.1% | 100,666 | +17.9% | 0.01% | -26.3% |
| Q4 2019 | $10,579,000 | +94.3% | 85,366 | +4.1% | 0.02% | +216.7% |
| Q3 2019 | $5,444,000 | +87.3% | 82,042 | +124.6% | 0.01% | 0.0% |
| Q2 2019 | $2,906,000 | -74.9% | 36,521 | -64.7% | 0.01% | -76.0% |
| Q1 2019 | $11,566,000 | +66.1% | 103,400 | +49.6% | 0.02% | +47.1% |
| Q4 2018 | $6,965,000 | +10.9% | 69,100 | +39.0% | 0.02% | +30.8% |
| Q3 2018 | $6,280,000 | +34.1% | 49,700 | -10.9% | 0.01% | +18.2% |
| Q2 2018 | $4,682,000 | +47.5% | 55,800 | +8.1% | 0.01% | +37.5% |
| Q1 2018 | $3,174,000 | +452.0% | 51,600 | +420.7% | 0.01% | +300.0% |
| Q3 2017 | $575,000 | -71.5% | 9,909 | -45.0% | 0.00% | -66.7% |
| Q2 2017 | $2,015,000 | -83.3% | 18,009 | -83.1% | 0.01% | -84.6% |
| Q1 2017 | $12,064,000 | +14.9% | 106,663 | +10.4% | 0.04% | 0.0% |
| Q4 2016 | $10,499,000 | -28.3% | 96,632 | +8.7% | 0.04% | -29.1% |
| Q3 2016 | $14,634,000 | -27.4% | 88,911 | -34.6% | 0.06% | -30.4% |
| Q2 2016 | $20,168,000 | +611.4% | 135,937 | +434.1% | 0.08% | +507.7% |
| Q1 2016 | $2,835,000 | -64.1% | 25,450 | -51.9% | 0.01% | -60.6% |
| Q4 2015 | $7,900,000 | -2.2% | 52,894 | +8.6% | 0.03% | -8.3% |
| Q3 2015 | $8,078,000 | -30.4% | 48,701 | +10.6% | 0.04% | -23.4% |
| Q2 2015 | $11,614,000 | +74.0% | 44,023 | +66.8% | 0.05% | +67.9% |
| Q1 2015 | $6,674,000 | +19.0% | 26,399 | -26.6% | 0.03% | +12.0% |
| Q4 2014 | $5,609,000 | +315.8% | 35,954 | +530.8% | 0.02% | +316.7% |
| Q3 2014 | $1,349,000 | +14.0% | 5,700 | +14.0% | 0.01% | 0.0% |
| Q2 2014 | $1,183,000 | -25.3% | 5,000 | +4.2% | 0.01% | -25.0% |
| Q1 2014 | $1,583,000 | – | 4,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |